Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
akcea therapeutics
alnylam pharmaceuticals
boston
2
×
boston blog main
boston top stories
clinical trials
fda
hereditary transthyretin amyloidosis
inotersen
life sciences
national blog main
national top stories
new york blog main
new york top stories
patisiran
rna interference
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
tafamidis
vyndaqel
2
×
andrew fire
barry greene
biotech
boston university
craig mello
dan ollendorf
drugs
john berk
john maraganore
mary o'donnell
nobel prize
onpattro
pfizer
regeneron pharmaceuticals
the amyloidosis foundation
the institute for clinical and economic review
What
alnylam
fda
medicine
afternoon
ago
alnylam’s
approve
approved
awaits
biological
crossed
decades
decision
discovered
drug
fingers
friday
gets
historic
history
landmark
making
ok
onpattro
patients
patisiran
pharmaceuticals
rna
rnai
specifically
time
trick
uses
Language
Current search:
vyndaqel
×
boston
×
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
